The device, developed by the Champalimaud Foundation, is being studied for the detection lung, ovarian and pancreatic cancer, tumors that worry professionals because they give warning signs, most of the time, in an advanced state.
A developed a non-invasive test that allows cancer to be detected through breathing. For now, it is in the testing phase applied to lung, pancreas and ovarian cancer.
Inspire and expire for three minutes. It’s enough so that the new hospital device collects the particles expelled by breathingwhich, after analysis, can serve as a method of detection of cancer.
Analysis of the results takes, for now, in testing phase clinical five and a half hours, but it can be done in half an hour.
A Artificial Intelligence is a fundamental part of the process. Classification and adds each person’s data depending on the chemical composition of each patient’s respiratory profile.
O model is being studied for the detection lung, ovarian and pancreatic cancertumors that worry professionals because they give warning signs, most of the time, in an advanced state.
In addition to being non-invasive, this test can have countless benefits for the sick and, in the long term, translate into savings on the NHS.
O device is currently in the clinical trials phase. The prediction is that it could be implemented in five years and the future could include application to other types of cancer.
